If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.
Menu closed
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Forsteo ® (teriparatide)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Forsteo Summary of Product Characteristics (SmPC)
Forsteo® (teriparatide): Patients with History of Lymphoma
In a patient with a history of lymphoma, take into consideration the risk of bone involvement, and the length of time the patient has been in remission before prescribing Forsteo.
Relevant
Information from Summary of Product Characteristics
Patients
with skeletal malignancies or bone metastases should be excluded from
treatment with teriparatide (contraindication).1
Forsteo
is contraindicated in patients with prior external beam or implant
radiation therapy to the skeleton.1
Clinical
Trial Experience
Patients
with a history of carcinoma in the previous five years or with a
current suspicion were excluded from participating in clinical trials
with teriparatide. However, patients with excised superficial lesions
of the skin and those with a history of carcinoma in situ of the
cervix or uterus were allowed to participate.2
There
was no apparent increase in the incidence of cancers among all study
participants treated with teriparatide compared with placebo during
clinical trials.2
References
1.
Forsteo [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
2.
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review:March 03, 2020
Are you satisfied with this content?
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com